Non-Cochrane · intervention · PM42590216
The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas.
Fu Xiaotong, Xu Shuiqing, Wang Ming · Journal of clinical medicine · 2026 · PubMed · doi:10.3390/jcm15156113
Findings
Population Patients with resectable squamous cell carcinoma (esophageal, head and neck, cervical, lung, cutaneous, oral)
191 findings
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.188 [0.145, 0.239] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year | Proportion 0.86 [0.75, 0.92] GRADE not reported 8 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Hongtao Duan 2021 (SCC subgroup) | Proportion 0.471 [0.409, 0.535] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Anatomical site: esophageal SCC (exploratory) | Proportion 0.474 [0.408, 0.541] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Zhang 2021 | Proportion 0.304 [0.267, 0.343] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Ruiqin Zhou 2023 | Proportion 0.185 [0.144, 0.235] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Ferrarotto 2021 | Proportion 0.478 [0.419, 0.538] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Checkpoint target: PD-L1 inhibitors (exploratory) | Proportion 0.240 [0.099, 0.476] GRADE not reported 1 study |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.605 [0.514, 0.690] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Jun Liu 2022 | Proportion 0.187 [0.145, 0.238] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Zhi Zhang 2022 | Proportion 0.472 [0.408, 0.536] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Guoqiang Yin 2023 | Proportion 0.590 [0.491, 0.682] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Xu 2024 | Proportion 0.297 [0.262, 0.335] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Gao 2020 | Proportion 0.471 [0.410, 0.534] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.449 [0.303, 0.604] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Jianping Wang 2023 | Proportion 0.876 [0.755, 0.942] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Yang 2021 | Proportion 0.301 [0.264, 0.340] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Shetal A. Patel 2023 | Proportion 0.168 [0.091, 0.289] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Duan 2022 | Proportion 0.299 [0.263, 0.337] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Zhenyang Zhang 2021 | Proportion 0.706 [0.582, 0.806] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Zhanjie Zhang 2023 | Proportion 0.842 [0.721, 0.916] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Pengfei Xu 2023 | Proportion 0.914 [0.891, 0.933] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Anatomical site: esophageal SCC (exploratory) | Proportion 0.849 [0.715, 0.926] GRADE not reported 2 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted W. Yang 2023 | Proportion 0.469 [0.407, 0.532] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Peng Shen 2022 | Proportion 0.597 [0.500, 0.686] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Huilai Lv 2024 | Proportion 0.184 [0.142, 0.236] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Guoqiang Yin 2023 | Proportion 0.189 [0.111, 0.303] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Huilai Lv 2023 | Proportion 0.175 [0.133, 0.226] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Y. Huang 2023 | Proportion 0.301 [0.265, 0.341] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Ting Qian 2024 | Proportion 0.822 [0.780, 0.858] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Dijian Shen 2021 | Proportion 0.186 [0.145, 0.237] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Chunyang Li 2024 | Proportion 0.160 [0.086, 0.279] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Peng Yang 2021 | Proportion 0.589 [0.492, 0.679] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.725 [0.534, 0.858] GRADE not reported 8 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Y. Yang 2022 | Proportion 0.305 [0.266, 0.347] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Yin 2023 | Proportion 0.469 [0.406, 0.533] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Ting Qian 2024 | Proportion 0.915 [0.896, 0.931] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Renata Ferrarotto 2021 | Proportion 0.727 [0.615, 0.816] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Kezhen Li 2023 | Proportion 0.307 [0.270, 0.346] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.308 [0.270, 0.350] GRADE not reported 32 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Xiaotao Huang 2022 | Proportion 0.600 [0.506, 0.687] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.931 [0.807, 0.978] GRADE not reported 2 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Anatomical site: esophageal SCC (exploratory) | Proportion 0.209 [0.107, 0.366] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Anatomical site: esophageal SCC (exploratory) | Proportion 0.284 [0.252, 0.318] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted He 2021 | Proportion 0.471 [0.409, 0.534] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Checkpoint target: PD-L1 inhibitors (exploratory) | Proportion 0.080 [0.015, 0.339] GRADE not reported 1 study |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Shetal A. Patel 2023 | Proportion 0.605 [0.514, 0.690] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Peng Shen 2022 | Proportion 0.181 [0.139, 0.233] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Y. Yang 2023 | Proportion 0.471 [0.407, 0.536] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Xiaotao Huang 2022 | Proportion 0.189 [0.111, 0.302] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Kezhen Li 2023 | Proportion 0.562 [0.475, 0.646] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Peng Yang 2021 | Proportion 0.696 [0.575, 0.795] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Weixiong Yang 2023 | Proportion 0.690 [0.570, 0.789] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.857 [0.747, 0.925] GRADE not reported 8 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Zhenyang Zhang 2021 | Proportion 0.187 [0.146, 0.237] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Can Liu 2024 | Proportion 0.177 [0.134, 0.230] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Xu 2024 | Proportion 0.470 [0.408, 0.533] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Jiang 2023 | Proportion 0.295 [0.260, 0.332] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate | Proportion 0.17 [0.10, 0.28] GRADE not reported 11 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Checkpoint target: PD-L1 inhibitors (exploratory) | Proportion 0.943 [0.798, 0.986] GRADE not reported 1 study |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Sehhoon Park 2023 | Proportion 0.603 [0.513, 0.687] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Anatomical site: esophageal SCC (exploratory) | Proportion 0.634 [0.521, 0.733] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Xiaofeng Chen 2022 | Proportion 0.173 [0.134, 0.221] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted X. Chen 2022 | Proportion 0.304 [0.267, 0.343] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Can Liu 2024 | Proportion 0.831 [0.716, 0.906] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Shen 2022 | Proportion 0.290 [0.258, 0.324] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year | Proportion 0.92 [0.90, 0.93] GRADE not reported 14 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.130 [0.071, 0.226] GRADE not reported 4 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year | Proportion 0.82 [0.79, 0.86] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Zhi Zhang 2022 | Proportion 0.879 [0.758, 0.944] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Lei Gao 2022 | Proportion 0.704 [0.581, 0.803] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.827 [0.777, 0.868] GRADE not reported 5 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Qian 2024 | Proportion 0.302 [0.265, 0.341] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Gao 2020 | Proportion 0.302 [0.266, 0.341] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Z. Zhang 2023 | Proportion 0.299 [0.263, 0.338] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Yuzhen Chen 2023 | Proportion 0.596 [0.498, 0.687] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Checkpoint target: PD-L1 inhibitors (exploratory) | Proportion 0.189 [0.085, 0.369] GRADE not reported 1 study |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Hongtao Duan 2021 (SCC subgroup) | Proportion 0.696 [0.573, 0.796] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Jin Peng 2024 | Proportion 0.917 [0.897, 0.933] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Lv 2023 | Proportion 0.459 [0.400, 0.518] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Li 2024 | Proportion 0.300 [0.263, 0.339] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Guo 2024 | Proportion 0.305 [0.268, 0.346] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Guoqiang Yin 2023 | Proportion 0.860 [0.734, 0.931] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Yiyu Guo 2024 | Proportion 0.716 [0.584, 0.819] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Jin Peng 2024 | Proportion 0.811 [0.776, 0.841] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Liu 2024 | Proportion 0.304 [0.266, 0.345] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.715 [0.591, 0.813] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Wu 2021 | Proportion 0.473 [0.410, 0.537] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Yuzhen Chen 2023 | Proportion 0.187 [0.108, 0.304] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Xiaotao Huang 2022 | Proportion 0.720 [0.602, 0.813] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Pengfei Xu 2023 | Proportion 0.579 [0.474, 0.678] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Jiang 2023 | Proportion 0.461 [0.402, 0.520] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Peng Yang 2021 | Proportion 0.165 [0.091, 0.279] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Ferrarotto 2021 | Proportion 0.295 [0.260, 0.332] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Yiyu Guo 2024 | Proportion 0.920 [0.901, 0.936] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Ting Qian 2024 | Proportion 0.570 [0.477, 0.659] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Lv 2024 | Proportion 0.307 [0.270, 0.346] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Wang 2023 | Proportion 0.467 [0.405, 0.530] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Guoqiang Yin 2023 | Proportion 0.916 [0.897, 0.932] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted J. Wang 2023 | Proportion 0.293 [0.259, 0.329] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Shetal A. Patel 2023 | Proportion 0.715 [0.591, 0.813] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Anatomical site: esophageal SCC (exploratory) | Proportion 0.907 [0.876, 0.931] GRADE not reported 8 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Y. Huang 2023 | Proportion 0.466 [0.404, 0.528] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Shujie Huang 2022 | Proportion 0.173 [0.133, 0.223] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Wang 2023 | Proportion 0.300 [0.263, 0.339] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Zhanjie Zhang 2023 | Proportion 0.187 [0.146, 0.237] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Anatomical site: esophageal SCC (exploratory) | Proportion 0.583 [0.454, 0.702] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Zhi Zhang 2022 | Proportion 0.917 [0.898, 0.933] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Jun Yin 2023 | Proportion 0.479 [0.418, 0.540] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted X. Chen 2022 | Proportion 0.469 [0.406, 0.532] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Yiyu Guo 2024 | Proportion 0.880 [0.769, 0.941] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.115 [0.066, 0.192] GRADE not reported 5 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Shen 2022 | Proportion 0.476 [0.415, 0.539] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate | Proportion 0.30 [0.27, 0.34] GRADE not reported 34 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Qi Fang 2023 | Proportion 0.913 [0.892, 0.930] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Y. Chen 2023 | Proportion 0.302 [0.265, 0.342] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Weixiong Yang 2023 | Proportion 0.190 [0.112, 0.303] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Renata Ferrarotto 2021 | Proportion 0.186 [0.144, 0.235] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Emily Y. Kim, BS 2024 | Proportion 0.827 [0.783, 0.863] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted He 2021 | Proportion 0.303 [0.266, 0.342] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Peng Shen 2022 | Proportion 0.181 [0.104, 0.298] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted W. Yang 2023 | Proportion 0.302 [0.265, 0.341] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Pengfei Xu 2023 | Proportion 0.690 [0.566, 0.791] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Anatomical site: esophageal SCC (exploratory) | Proportion 0.199 [0.152, 0.256] GRADE not reported 15 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Hongtao Duan 2021 (SCC subgroup) | Proportion 0.303 [0.267, 0.342] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) | Proportion 0.70 [0.59, 0.80] GRADE not reported 14 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Jianping Wang 2023 | Proportion 0.916 [0.897, 0.932] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Peng Yang 2021 | Proportion 0.828 [0.784, 0.865] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate | Proportion 0.59 [0.50, 0.67] GRADE not reported 14 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Yingnan Yang 2023 | Proportion 0.152 [0.090, 0.246] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Hongtao Duan 2021 (SCC subgroup) | Proportion 0.573 [0.479, 0.662] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Jin Peng 2024 | Proportion 0.677 [0.559, 0.776] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted J. Wang 2023 | Proportion 0.457 [0.400, 0.515] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Liu 2024 | Proportion 0.479 [0.417, 0.541] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Huang 2022 | Proportion 0.476 [0.415, 0.538] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Checkpoint target: PD-L1 inhibitors (exploratory) | Proportion 0.829 [0.667, 0.921] GRADE not reported 1 study |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Z. Zhang 2023 | Proportion 0.460 [0.401, 0.520] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.828 [0.782, 0.866] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.168 [0.091, 0.289] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Yingnan Yang 2023 (cohort 1) | Proportion 0.721 [0.602, 0.816] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Qi Fang 2023 | Proportion 0.839 [0.787, 0.880] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.916 [0.897, 0.932] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Emily Y. Kim, BS 2024 | Proportion 0.918 [0.900, 0.934] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Yin 2023 | Proportion 0.299 [0.263, 0.339] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Lv 2022 | Proportion 0.302 [0.264, 0.342] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Pengfei Xu 2023 | Proportion 0.841 [0.786, 0.883] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Shetal A. Patel 2023 | Proportion 0.916 [0.897, 0.932] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.924 [0.900, 0.943] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Zhi Zhang 2022 | Proportion 0.304 [0.267, 0.344] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Yiyu Guo 2024 | Proportion 0.175 [0.132, 0.227] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate | Proportion 0.47 [0.41, 0.53] GRADE not reported 26 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year progression-free survival (PFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Shetal A. Patel 2023 | Proportion 0.828 [0.782, 0.866] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Y. Yang 2023 | Proportion 0.303 [0.265, 0.343] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.349 [0.242, 0.474] GRADE not reported 9 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Zhang 2021 | Proportion 0.468 [0.406, 0.531] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Shen 2021 | Proportion 0.300 [0.264, 0.340] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Weixiong Yang, 2023 | Proportion 0.172 [0.134, 0.217] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Checkpoint target: PD-L1 inhibitors (exploratory) | Proportion 0.568 [0.393, 0.727] GRADE not reported 1 study |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Checkpoint target: PD-L1 inhibitors (exploratory) | Proportion 0.380 [0.227, 0.561] GRADE not reported 1 study |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Park 2023 | Proportion 0.477 [0.418, 0.538] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Renata Ferrarotto 2021 | Proportion 0.916 [0.897, 0.932] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Lv 2024 | Proportion 0.475 [0.412, 0.540] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Peng Yang 2021 | Proportion 0.916 [0.897, 0.932] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Duan 2022 | Proportion 0.465 [0.404, 0.527] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Renata Ferrarotto 2021 | Proportion 0.853 [0.730, 0.925] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Weixiong Yang 2023 | Proportion 0.572 [0.480, 0.659] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Can Liu 2024 | Proportion 0.917 [0.897, 0.934] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Kai Wang 2023 | Proportion 0.185 [0.143, 0.235] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Yang Yang 2022 | Proportion 0.188 [0.145, 0.239] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Leave-one-out sensitivity analysis: omitted Y. Chen 2023 | Proportion 0.474 [0.412, 0.538] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Emily Y. Kim 2024 | Proportion 0.716 [0.596, 0.811] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Zhou 2023 | Proportion 0.302 [0.265, 0.341] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Huang 2022 | Proportion 0.303 [0.267, 0.342] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Major pathological response (MPR) rate Checkpoint target: PD-1 inhibitors (exploratory) | Proportion 0.479 [0.418, 0.540] GRADE not reported 25 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year overall survival (OS) rate 1 year · Leave-one-out sensitivity analysis: omitted Huilai Lv 2024 | Proportion 0.919 [0.900, 0.935] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Jun Liu 2022 | Proportion 0.593 [0.493, 0.686] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Yingying Huang 2023 | Proportion 0.179 [0.103, 0.293] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Clinical complete response (cCR) rate Leave-one-out sensitivity analysis: omitted Dijian Shen 2021 | Proportion 0.151 [0.086, 0.253] GRADE not reported 10 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Hongtao Duan 2022 | Proportion 0.177 [0.136, 0.227] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Huilai Lv 2022 | Proportion 0.186 [0.143, 0.238] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Objective response rate (ORR) Leave-one-out sensitivity analysis: omitted Kezhen Li 2023 | Proportion 0.663 [0.553, 0.757] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Anatomical site: esophageal SCC (exploratory) | Proportion 0.834 [0.699, 0.915] GRADE not reported 6 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Yingying Huang 2023 | Proportion 0.182 [0.140, 0.233] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Kim 2024 | Proportion 0.297 [0.262, 0.335] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) | Proportion 0.18 [0.14, 0.23] GRADE not reported 20 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Grade 3-4 adverse events (incidence) Leave-one-out sensitivity analysis: omitted Wenwu He 2021 | Proportion 0.179 [0.138, 0.230] GRADE not reported 19 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Anatomical site: non-esophageal SCC (exploratory) | Proportion 0.588 [0.452, 0.712] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Jun Yin 2023 | Proportion 0.303 [0.268, 0.341] GRADE not reported 33 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | 1-year disease-free survival (DFS) rate 1 year · Leave-one-out sensitivity analysis: omitted Huilai Lv 2022 | Proportion 0.833 [0.714, 0.908] GRADE not reported 7 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Partial response (PR) rate Leave-one-out sensitivity analysis: omitted Yingying Huang 2023 | Proportion 0.593 [0.497, 0.683] GRADE not reported 13 studies |
| Neoadjuvant immune checkpoint blockade (PD-1/PD-L1), with or without chemotherapy, before surgery | None (single-arm pooled proportions; no comparator) | Pathological complete response (pCR) rate Leave-one-out sensitivity analysis: omitted Wu 2021 | Proportion 0.300 [0.263, 0.339] GRADE not reported 33 studies |
Included primary studies 44
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Shen 2022 Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. PMID:35972629 | 2022 | 1 other review | not stated | not extracted yet |
| Chen 2023 Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an… PMID:36759013 | 2023 | this review only | not stated | not extracted yet |
| Chen 2023 Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm,… PMID:38249875 | 2023 | this review only | not stated | not extracted yet |
| Duan 2021 Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label,… PMID:33718040 | 2021 | this review only | not stated | not extracted yet |
| Duan 2022 Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE). PMID:35720388 | 2022 | this review only | not stated | not extracted yet |
| Fang 2023 PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and… PMID:37804437 | 2023 | this review only | not stated | not extracted yet |
| Ferrarotto 2021 Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and… PMID:34187851 | 2021 | this review only | not stated | not extracted yet |
| Gao 2022 Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a… PMID:35557591 | 2022 | this review only | not stated | not extracted yet |
| Guo 2024 Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A… PMID:38941666 | 2024 | this review only | not stated | not extracted yet |
| He 2022 Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma. PMID:35305102 | 2022 | this review only | not stated | not extracted yet |
| Hong 2022 Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal… PMID:34988773 | 2022 | this review only | not stated | not extracted yet |
| Huang 2022 Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World… PMID:35911702 | 2022 | this review only | not stated | not extracted yet |
| Huang 2022 Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma… PMID:36224603 | 2022 | this review only | not stated | not extracted yet |
| Huang 2023 Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate… PMID:37288582 | 2023 | this review only | not stated | not extracted yet |
| Kim 2024 Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma. PMID:38546619 | 2024 | this review only | not stated | not extracted yet |
| Li 2024 Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. PMID:38048802 | 2024 | this review only | not stated | not extracted yet |
| Li 2024 Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell… PMID:38273405 | 2024 | this review only | not stated | not extracted yet |
| Liu 2022 Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous… PMID:35338088 | 2022 | this review only | not stated | not extracted yet |
| Liu 2024 Real-world retrospective study of anti-PD-1 antibody in combination with chemotherapy as a neoadjuvant treatment strategy for locally… PMID:39144348 | 2024 | this review only | not stated | not extracted yet |
| Lv 2022 Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma. PMID:35574384 | 2022 | this review only | not stated | not extracted yet |
| Lv 2023 The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell… PMID:36741358 | 2022 | this review only | not stated | not extracted yet |
| Lv 2024 Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma. PMID:38760614 | 2024 | this review only | not stated | not extracted yet |
| Park 2024 Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study. PMID:37846467 | 2024 | this review only | not stated | not extracted yet |
| Patel 2023 A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma. PMID:37395170 | 2023 | this review only | not stated | not extracted yet |
| Peng 2024 Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced… PMID:38358522 | 2024 | this review only | not stated | not extracted yet |
| Qian 2024 Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. PMID:38497137 | 2024 | this review only | not stated | not extracted yet |
| Shen 2021 The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. PMID:33708420 | 2021 | this review only | not stated | not extracted yet |
| Wang 2023 Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous… PMID:37045666 | 2023 | this review only | not stated | not extracted yet |
| Wang 2023 Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck… PMID:37583698 | 2023 | this review only | not stated | not extracted yet |
| Wang 2023 Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung… PMID:38205138 | 2023 | this review only | not stated | not extracted yet |
| Wang 2024 Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm,… PMID:37676100 | 2024 | this review only | not stated | not extracted yet |
| Wu 2021 Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. PMID:34277047 | 2021 | this review only | not stated | not extracted yet |
| Xu 2023 Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell… PMID:37837458 | 2023 | this review only | not stated | not extracted yet |
| Xu 2024 Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer. PMID:38458635 | 2024 | this review only | not stated | not extracted yet |
| Yang 2021 Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study. PMID:34809658 | 2021 | this review only | not stated | not extracted yet |
| Yang 2022 Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective… PMID:35649396 | 2022 | this review only | not stated | not extracted yet |
| Yang 2024 Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm… PMID:38051925 | 2024 | this review only | not stated | not extracted yet |
| Yin 2022 The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell… PMID:35795828 | 2022 | this review only | not stated | not extracted yet |
| Yin 2023 Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. PMID:37488287 | 2023 | this review only | not stated | not extracted yet |
| Zhang 2022 Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical… PMID:35766967 | 2022 | this review only | not stated | not extracted yet |
| Zhang 2022 Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2… PMID:36311804 | 2022 | this review only | not stated | not extracted yet |
| Zhao 2023 Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study. PMID:36762056 | 2023 | this review only | not stated | not extracted yet |
| Zhao 2024 Complete responses after neoadjuvant toripalimab and chemoradiotherapy for oesophageal squamous cell carcinoma: in situ and ex vivo 3.0 T… PMID:37931155 | 2024 | this review only | not stated | not extracted yet |
| Zhou 2023 Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study. PMID:37161374 | 2023 | this review only | not stated | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
| Review | Shared studies | Jaccard |
|---|---|---|
| Two-year follow-up outcomes of neoadjuvant therapy in oral squamous cell carcinoma: an exploratory systematic review and meta-analysis. (2026) | 1 | 0.02 |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients with squamous cell carcinoma of the esophagus, head and neck, cervix, lung, skin or oral cavity | Patients with resectable SCC (n=2586): esophageal 29 studies, head and neck 8, lung 3, oral 2, cervical 1, cutaneous 1 |
| Intervention | Neoadjuvant immunotherapy (immune checkpoint blockade) with or without chemotherapy before surgery | Neoadjuvant PD-1 or PD-L1 inhibitor with or without chemotherapy (PD-1 based in nearly all studies) |
| Comparison | Not specified (single-arm studies eligible) | None (single-arm proportions) |
| Outcomes | Objective response rate, clinical complete response, pathological complete response, partial response, major pathological response, 1-year PFS, DFS and OS, grade 3-4 adverse events | ORR (k=14), cCR (k=11), pCR (k=34), PR (k=14), MPR (k=26), 1-year PFS (k=7), DFS (k=8), OS (k=14), grade 3-4 adverse events (k=20) |
| Study designs | Prospective or retrospective clinical studies including single-arm trials and observational cohorts | 44 studies, predominantly prospective single-arm trials and retrospective cohorts; no randomized trials |
| Timing | 1-year survival (9 to 15 months window) | 1-year survival outcomes |
AMSTAR 2 items
Two independent extractors rated each item. Their ratings are shown side by side because they have not been reconciled yet. The overall rating follows Shea et al. 2017: one critical flaw gives Low, more than one gives Critically Low.
| Item | Extractor A | Extractor B | Agree |
|---|---|---|---|
| 1Research question includes PICO components | Yes | Yes | yes |
| 2Protocol established before the reviewcritical | Partial Yes | Partial Yes | yes |
| 3Choice of study designs explained | No | Yes | no |
| 4Comprehensive literature searchcritical | Partial Yes | Partial Yes | yes |
| 5Study selection in duplicate | Yes | Yes | yes |
| 6Data extraction in duplicate | Yes | Yes | yes |
| 7List of excluded studies with reasonscritical | No | No | yes |
| 8Included studies described in detail | Partial Yes | Partial Yes | yes |
| 9Risk of bias assessed satisfactorilycritical | NRSI: Partial Yes · RCT: N/A | NRSI: Partial Yes | no |
| 10Funding of included studies reported | No | No | yes |
| 11Appropriate meta-analysis methodscritical | NRSI: Yes · RCT: N/A | NRSI: Yes | no |
| 12Impact of risk of bias on the pooled results | No | No | yes |
| 13Risk of bias accounted for in interpretationcritical | Yes | Yes | yes |
| 14Heterogeneity explained | Yes | Yes | yes |
| 15Publication bias investigatedcritical | Yes | Yes | yes |
| 16Conflicts of interest reported | Yes | Yes | yes |
| Overall | Low | Low | yes |